<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472574</url>
  </required_header>
  <id_info>
    <org_study_id>20150403</org_study_id>
    <nct_id>NCT02472574</nct_id>
  </id_info>
  <brief_title>Dose-effect Relationship of Rt-PA on ICH Evacuation</brief_title>
  <official_title>Phase 2 Study of Rt-PA Dose-effect Relationship on ICH Evacuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the optimal dose of rt-PA in the treatment of
      intracerebral hemorrhage (ICH) using a combination of minimally invasive surgery and clot
      lysis with rt-PA。
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The minimally invasive surgery (MIS) plus recombinant tissue plasminogen activator (rt-PA) is
      one of the best choices in the treatment of a large-scale deep supratentorial intracerebral
      hematoma. It uses hardware access technology, in a relatively short time to enter the
      hematoma center with favourable accuracy and safety.

      The dose of rt-PA range from 0.3 mg to 4.0 mg in different research。We propose to determine
      the optimal dose of rt-PA with three dose control groups.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of clot size removal</measure>
    <time_frame>baseline to 24 hours(±12) post the last dose of rt-PA</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intracranial infection</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of rebleeding</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow outcome scale gos</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow outcome scale gos</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rankin stroke impact scale</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rankin stroke impact scale</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Hypertensive Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>0.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the 0.3 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle, followed by up to 4 doses of 0.3 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the 0.5 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 0.5 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the 1.0 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YL-1 type of intracranial hematoma puncture needle</intervention_name>
    <description>YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.</description>
    <arm_group_label>0.3 mg</arm_group_label>
    <arm_group_label>0.5 mg</arm_group_label>
    <arm_group_label>1.0 mg</arm_group_label>
    <other_name>aspiration drainage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rt-PA</intervention_name>
    <description>Up to 4 doses of 0.3~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.</description>
    <arm_group_label>0.3 mg</arm_group_label>
    <arm_group_label>0.5 mg</arm_group_label>
    <arm_group_label>1.0 mg</arm_group_label>
    <other_name>recombinant tissue plasminogen activator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80.

          -  GCS &lt; 14 or a NIHSS &gt; or equal to 6.

          -  Spontaneous supratentorial ICH ≥ 20 mL diagnosed using radiographic imaging (CT, CTA,
             etc.)

          -  Symptoms less than 24 hours prior to diagnostic CT(dCT) scan (an unknown time of
             symptom onset is exclusionary).

          -  Six-hour clot size equal to the most previous clot size (within 5 mL) as determined by
             additional CT scans at least 6 hours apart using the ABC/2 method.

          -  Intention to initiate surgery between 12 and 72 hours after after diagnostic CT. First
             dose can be given within 76 hours after dCT (delays for post surgical stabilization of
             catheter bleeding).

          -  SBP &lt; 180 mmHg sustained for 6 hours recorded closest to time of randomization.

          -  Historical Rankin score of 0 or 1.

          -  Negative pregnancy test.

        Exclusion Criteria:

          -  Infratentorial hemorrhage (any involvement of the midbrain or lower brainstem as
             demonstrated by radiograph or complete third nerve palsy).

          -  Irreversible impaired brain stem function (bilateral fixed, dilated pupils and
             extensor motor posturing), GCS ≤ 4.

          -  Intraventricular hemorrhage requiring treatment with extraventricular drainage
             (obstruction of third and fourth ventricles).

          -  Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, Moyamoya
             disease diagnosed with radiographic imaging.

          -  Any irreversible coagulopathy or known clotting disorder. or having the experience of
             the use of anticoagulant drug.

          -  Platelet count &lt; 100,000, INR &gt; 1.7, or an elevated prothrombin time (PT) or activated
             partial thromboplastin time (aPTT).

          -  Positive urine or serum pregnancy test in pre-menopausal female subjects without a
             documented history of surgical sterilization.

          -  Any concurrent serious illness that would interfere with the safety assessments
             including hepatic, renal, gastroenterologic, respiratory, cardiovascular,
             endocrinologic, immunologic, and hematologic disease.

          -  Historical Rankin score greater than or equal to 2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhu Suiqiang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hubei Tongji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Morgan T, Zuccarello M, Narayan R, Keyl P, Lane K, Hanley D. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta Neurochir Suppl. 2008;105:147-51.</citation>
    <PMID>19066101</PMID>
  </reference>
  <reference>
    <citation>Mould WA, Carhuapoma JR, Muschelli J, Lane K, Morgan TC, McBee NA, Bistran-Hall AJ, Ullman NL, Vespa P, Martin NA, Awad I, Zuccarello M, Hanley DF; MISTIE Investigators. Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Stroke. 2013 Mar;44(3):627-34. doi: 10.1161/STROKEAHA.111.000411. Epub 2013 Feb 7.</citation>
    <PMID>23391763</PMID>
  </reference>
  <reference>
    <citation>Lian LF, Xu F, Tang ZP, Xue Z, Liang QM, Hu Q, Zhu WH, Kang HC, Liu XY, Wang FR, Zhu SQ. Intraclot recombinant tissue-type plasminogen activator reduces perihematomal edema and mortality in patients with spontaneous intracerebral hemorrhage. J Huazhong Univ Sci Technolog Med Sci. 2014 Apr;34(2):165-71. doi: 10.1007/s11596-014-1252-x. Epub 2014 Apr 8.</citation>
    <PMID>24710926</PMID>
  </reference>
  <reference>
    <citation>Tang ZP, Shi YH, Yin XP, Xu JZ, Zhang SM, Wang W. Modifying the details of aspiration operation may contribute to the improvement of prognosis of patients with ICH. Turk Neurosurg. 2012;22(1):13-20. doi: 10.5137/1019-5149.JTN.4219-11.0.</citation>
    <PMID>22274965</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <last_update_submitted>June 11, 2015</last_update_submitted>
  <last_update_submitted_qc>June 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Suiqiang Zhu</investigator_full_name>
    <investigator_title>director of the neurology</investigator_title>
  </responsible_party>
  <keyword>Intracerebral Hemorrhage</keyword>
  <keyword>minimally invasive surgery</keyword>
  <keyword>recombinant tissue plasminogen activator</keyword>
  <keyword>Dose-effect Relationship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Intracranial Hemorrhage, Hypertensive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

